<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01725191</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02163</org_study_id>
    <secondary_id>NCI-2012-02163</secondary_id>
    <secondary_id>COG-ADVL1111</secondary_id>
    <secondary_id>ADVL1111</secondary_id>
    <secondary_id>ADVL1111</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT01725191</nct_id>
  </id_info>
  <brief_title>Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197) in Children With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of tivantinib in treating younger&#xD;
      patients with solid tumors that have returned after a period of improvement or have not&#xD;
      responded to treatment. Tivantinib may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of tivantinib&#xD;
      administered orally twice daily to children with refractory solid tumors.&#xD;
&#xD;
      II. To define and describe the toxicities of tivantinib administered on this schedule.&#xD;
&#xD;
      III. To characterize the pharmacokinetics of tivantinib (capsule as well as powder&#xD;
      formulation) in children with refractory cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the antitumor activity of tivantinib within the confines of a&#xD;
      phase 1 study.&#xD;
&#xD;
      II. To preliminarily investigate whether cytochrome P450 (CYP450) polymorphisms impact&#xD;
      pharmacokinetics or toxicity of tivantinib.&#xD;
&#xD;
      III. To preliminarily investigate whether tumor c-Met and/or hepatocyte growth factor (HGF)&#xD;
      expression or downstream c-Met signaling correlate with clinical response to tivantinib.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive tivantinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats&#xD;
      every 28 days for up to 12 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of tivantinib</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6 and 8-12 hours day 1 of course 1; pre-dose day 1 of course 2</time_frame>
    <description>The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease response assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Will be reported descriptively.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CYP450 polymorphisms</measure>
    <time_frame>Baseline</time_frame>
    <description>Relationships between CYP450 polymorphisms and pharmacokinetics and toxicity will be explored.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor c-met expression</measure>
    <time_frame>Baseline</time_frame>
    <description>Relationships between tumor c-met expression and response will be explored.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Childhood Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (tivantinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tivantinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (tivantinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivantinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (tivantinib)</arm_group_label>
    <other_name>ARQ 197</other_name>
    <other_name>ARQ-197</other_name>
    <other_name>c-Met Inhibitor ARQ 197</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PART A: Patients on dose levels -1 or 1 must have a body surface area (BSA) &gt;= 0.65&#xD;
             m^2 at the time of study enrollment; patients on dose levels 2 or 3 must have a BSA &gt;=&#xD;
             0.45 m^2 at the time of study enrollment&#xD;
&#xD;
          -  PART B: There is no minimum body surface area requirement for patients in part B&#xD;
&#xD;
          -  Patients with relapsed or refractory solid tumors including central nervous system&#xD;
             (CNS) tumors are eligible; patients must have had histologic verification of&#xD;
             malignancy at original diagnosis or relapse except in patients with intrinsic brain&#xD;
             stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of&#xD;
             cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or&#xD;
             beta-human chorionic gonadotropin (HCG)&#xD;
&#xD;
          -  Patients must have either measurable or evaluable disease&#xD;
&#xD;
          -  Patient's current disease state must be one for which there is no known curative&#xD;
             therapy or therapy proven to prolong survival with an acceptable quality of life&#xD;
&#xD;
          -  Karnofsky &gt;= 50% for patients &gt; 16 years of age and Lansky &gt;= 50 for patients =&lt; 16&#xD;
             years of age; note: neurologic deficits in patients with CNS tumors must have been&#xD;
             stable or improving for at least 7 days prior to study enrollment; patients who are&#xD;
             unable to walk because of paralysis, but who are up in a wheelchair, will be&#xD;
             considered ambulatory for the purpose of assessing the performance score&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             anti-cancer chemotherapy:&#xD;
&#xD;
               -  Myelosuppressive chemotherapy: At least 21 days after the last dose of&#xD;
                  myelosuppressive chemotherapy (42 days if prior nitrosourea)&#xD;
&#xD;
               -  Hematopoietic growth factors: At least 14 days after the last dose of a&#xD;
                  long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth&#xD;
                  factor; for agents that have known adverse events occurring beyond 7 days after&#xD;
                  administration, this period must be extended beyond the time during which adverse&#xD;
                  events are known to occur; the duration of this interval must be discussed with&#xD;
                  the study chair&#xD;
&#xD;
               -  Biologic (anti-neoplastic agent): At least 7 days after the last dose of a&#xD;
                  biologic agent; for agents that have known adverse events occurring beyond 7 days&#xD;
                  after administration, this period must be extended beyond the time during which&#xD;
                  adverse events are known to occur; the duration of this interval must be&#xD;
                  discussed with the study chair&#xD;
&#xD;
               -  Immunotherapy: At least 42 days after the completion of any type of&#xD;
                  immunotherapy, e.g. tumor vaccines&#xD;
&#xD;
               -  Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose&#xD;
                  of a monoclonal antibody&#xD;
&#xD;
               -  Radiation therapy (XRT): At least 14 days after local palliative XRT (small&#xD;
                  port); at least 150 days must have elapsed if prior total-body irradiation (TBI),&#xD;
                  craniospinal XRT or if &gt;= 50% radiation of pelvis; at least 42 days must have&#xD;
                  elapsed if other substantial bone marrow (BM) radiation&#xD;
&#xD;
               -  Stem cell infusion without TBI: No evidence of active graft vs. host disease and&#xD;
                  at least 84 days must have elapsed after transplant or stem cell infusion&#xD;
&#xD;
               -  Patients may not have received prior therapy with tivantinib&#xD;
&#xD;
          -  Peripheral absolute neutrophil count (ANC) &gt;= 1000/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3 (transfusion independent, defined as not receiving&#xD;
             platelet transfusions for at least 7 days prior to enrollment)&#xD;
&#xD;
          -  Patients with known bone marrow involvement will be eligible for study provided they&#xD;
             meet the blood counts above (may receive transfusions provided they are not known to&#xD;
             be refractory to red cell or platelet transfusions); these patients will not be&#xD;
             evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients with a&#xD;
             solid tumor must be evaluable for hematologic toxicity for the dose escalation part of&#xD;
             the study; if dose-limiting hematologic toxicity is observed, all subsequent patients&#xD;
             enrolled must be evaluable for hematologic toxicity&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70&#xD;
             ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:&#xD;
&#xD;
               -  1 to &lt; 2 years: 0.6 mg/dL&#xD;
&#xD;
               -  2 to &lt; 6 years: 0.8 mg/dL&#xD;
&#xD;
               -  6 to &lt; 10 years: 1.0 mg/dL&#xD;
&#xD;
               -  10 to &lt; 13 years: 1.2 mg/dL&#xD;
&#xD;
               -  13 to &lt; 16 years: 1.5 mg/dL (males); 1.4 mg/dL (females)&#xD;
&#xD;
               -  &gt;= 16 years: 1.7 mg/dL (males); 1.4 mg/dL (females)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated + unconjugated) =&lt; 1.5 x upper limit of normal (ULN) for&#xD;
             age&#xD;
&#xD;
          -  Serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 110&#xD;
             U/L; for the purpose of this study, the ULN for SGPT is 45 U/L&#xD;
&#xD;
          -  Serum albumin &gt;= 2 g/dL&#xD;
&#xD;
          -  All patients and/or their parents or legally authorized representatives must sign a&#xD;
             written informed consent; assent, when appropriate, will be obtained according to&#xD;
             institutional guidelines&#xD;
&#xD;
          -  Tissue blocks or slides must be sent; if tissue blocks or slides are unavailable, the&#xD;
             study chair must be notified prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women will not be entered on this study; pregnancy tests&#xD;
             must be obtained in girls who are post-menarchal; males or females of reproductive&#xD;
             potential may not participate unless they have agreed to use an effective&#xD;
             contraceptive method&#xD;
&#xD;
          -  Patients receiving corticosteroids who have not been on a stable or decreasing dose of&#xD;
             corticosteroid for at least 7 days prior to enrollment are not eligible&#xD;
&#xD;
          -  Patients who are currently receiving another investigational drug are not eligible&#xD;
&#xD;
          -  Patients who are currently receiving other anti-cancer agents are not eligible&#xD;
&#xD;
          -  Patients who are receiving cyclosporine, tacrolimus or other agents to prevent&#xD;
             graft-versus-host disease post bone marrow transplant are not eligible for this trial&#xD;
&#xD;
          -  Patients must not be receiving any of the following for at least 24 hours prior to&#xD;
             enrollment: omeprazole, esoprazole, lansoprazole, pantoprazole, rifampin, omeprazole,&#xD;
             fluvoxamine, or moclobemide&#xD;
&#xD;
          -  Patients must not be receiving any of the following for at least 24 hours prior to&#xD;
             enrollment: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole,&#xD;
             nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO),&#xD;
             voriconazole, rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine,&#xD;
             phenobarbital, or St. John's Wort&#xD;
&#xD;
          -  Nasogastric or G tube administration is not allowed; patients in part A must be able&#xD;
             to swallow capsules&#xD;
&#xD;
          -  Patients who have an uncontrolled infection are not eligible&#xD;
&#xD;
          -  Patients who have received a prior solid organ transplantation are not eligible&#xD;
&#xD;
          -  Patients who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study are not eligible&#xD;
&#xD;
          -  Patients with &gt;= grade 2 bradycardia or with a known history &gt;= grade 2 cardiac&#xD;
             arrhythmia are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Geller</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center-Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 8, 2012</study_first_submitted>
  <study_first_submitted_qc>November 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01725191
org study id: NCI-2012-02163
secondary id: NCI-2012-02163
secondary id: COG-ADVL1111
secondary id: ADVL1111
secondary id: ADVL1111
secondary id: U01CA097452
nct id: NCT01725191
lead sponsor: 
This phase I trial studies the side effects and best dose of tivantinib in treating younger
      patients with solid tumors that have returned after a period of improvement or have not
      responded to treatment. Tivantinib may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth.
PRIMARY OBJECTIVES:

      I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of tivantinib
      administered orally twice daily to children with refractory solid tumors.

      II. To define and describe the toxicities of tivantinib administered on this schedule.

      III. To characterize the pharmacokinetics of tivantinib (capsule as well as powder
      formulation) in children with refractory cancer.

      SECONDARY OBJECTIVES:

      I. To preliminarily define the antitumor activity of tivantinib within the confines of a
      phase 1 study.

      II. To preliminarily investigate whether cytochrome P450 (CYP450) polymorphisms impact
      pharmacokinetics or toxicity of tivantinib.

      III. To preliminarily investigate whether tumor c-Met and/or hepatocyte growth factor (HGF)
      expression or downstream c-Met signaling correlate with clinical response to tivantinib.

      OUTLINE: This is a dose-escalation study.

      Patients receive tivantinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats
      every 28 days for up to 12 courses in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up for 30 days.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: MTD defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
time frame: 28 days
measure: Pharmacokinetic (PK) parameters of tivantinib
time frame: Pre-dose, 1, 2, 4, 6 and 8-12 hours day 1 of course 1; pre-dose day 1 of course 2
description: The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).
measure: Disease response assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
time frame: Up to 30 days after completion of study treatment
description: Will be reported descriptively.
measure: CYP450 polymorphisms
time frame: Baseline
description: Relationships between CYP450 polymorphisms and pharmacokinetics and toxicity will be explored.
measure: Tumor c-met expression
time frame: Baseline
description: Relationships between tumor c-met expression and response will be explored.
arm group label: Treatment (tivantinib)
arm group type: Experimental
description: Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
intervention type: Other
intervention name: Laboratory Biomarker Analysis
description: Correlative studies
arm group label: Treatment (tivantinib)
intervention type: Other
intervention name: Pharmacological Study
description: Correlative studies
arm group label: Treatment (tivantinib)
intervention type: Drug
intervention name: Tivantinib
description: Given PO
arm group label: Treatment (tivantinib)
other name: ARQ 197
other name: ARQ-197
other name: c-Met Inhibitor ARQ 197
criteria: 
gender: All
minimum age: 13 Months
maximum age: 21 Years
healthy volunteers: No
last name: James Geller
role: Principal Investigator
affiliation: COG Phase I Consortium
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Canada
country: United States
responsible party type: Sponsor